Aging and infertility in women

Dl, Keefe

doi:10.1016/j.fertnstert.2004.05.032

Cited by 13 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SRI treatment limited to the luteal phase appears to be as effective as daily administration (29–37), indicating a much shorter onset of action of these drugs when used for premenstrual dysphoric disorder than when used for depression and anxiety disorders. There is also evidence that certain ovulation-inhibiting hormonal treatments (38, 39) and gonadotropin-releasing hormone (GnRH) agonists (40–45) are efficacious in the treatment of premenstrual syndrome/premenstrual dysphoric disorder, and there is no reason to believe that these treatments would be effective in other mood disorders (41). While GnRH agonist treatment appears to be effective for both the behavioral and physical symptoms of premenstrual syndrome/premenstrual dysphoric disorder in the majority of cases, hormone add-back is required to reduce the adverse sequelae of long-term hypogonadism.…”

Section: Addressing Requirements For Diagnostic Categorymentioning

confidence: 99%

“…Furthermore, in no other psychiatric disorder do SRIs reduce symptoms with as short an onset of action as in premenstrual dysphoric disorder. Likewise, premenstrual dysphoric disorder is responsive to treatment with oral contraceptives containing the unique progestin drospirenone (38, 39) as well as to ovarian suppression with GnRH agonists (45, 46). …”

Section: Addressing Requirements For Diagnostic Categorymentioning

confidence: 99%

See 1 more Smart Citation

Premenstrual Dysphoric Disorder: Evidence for a New Category for DSM-5

Epperson¹,

Steiner²,

Hartlage³

et al. 2012

AJP

280

194

View full text Add to dashboard Cite

Premenstrual dysphoric disorder, which affects 2%–5% of premenopausal women, was included in Appendix B of DSM-IV, “Criterion Sets and Axes Provided for Further Study.” Since then, aided by the inclusion of specific and rigorous criteria in DSM-IV, there has been an explosion of research on the epidemiology, phenomenology, pathogenesis, and treatment of the disorder. In 2009, the Mood Disorders Work Group for DSM-5 convened a group of experts to examine the literature on premenstrual dysphoric disorder and provide recommendations regarding the appropriate criteria and placement for the disorder in DSM-5. Based on thorough review and lengthy discussion, the work group proposed that the information on the diagnosis, treatment, and validation of the disorder has matured sufficiently for it to qualify as a full category in DSM-5. A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the disorder and encourage the growth of evidence-based research, ultimately leading to new treatments.

show abstract